share_log

Abbott Laboratories | 8-K: Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range

Abbott Laboratories | 8-K: Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range

雅培 | 8-K：雅培公佈2024年第三季度業績並提高全年每股收益指導區間的中點
美股SEC公告 ·  2024/10/16 05:42

Moomoo AI 已提取核心訊息

Abbott reported Q3 2024 sales of $10.6 billion, up 4.9% year-over-year, with organic sales growth of 8.2% excluding COVID-19 testing. Medical Devices led growth with 13.3% organic increase, driven by strong performance in Diabetes Care, Structural Heart, and Electrophysiology. The company posted GAAP EPS of $0.94 and adjusted EPS of $1.21.The company raised its full-year 2024 adjusted EPS guidance to $4.64-$4.70, reflecting continued momentum across its diversified portfolio. Abbott's board authorized a new $7 billion share repurchase program in October. Notable developments include a partnership with Medtronic for CGM integration and the U.S. launch of Lingo, Abbott's first over-the-counter continuous glucose monitoring system.Regional performance showed U.S. sales growing 10.1% to $4.2 billion, while international sales increased 1.7% to $6.4 billion. The company maintained its full-year 2024 organic sales growth guidance of 9.5-10.0%, excluding COVID-19 testing sales, which declined to $265 million in Q3 compared to $305 million last year.
Abbott reported Q3 2024 sales of $10.6 billion, up 4.9% year-over-year, with organic sales growth of 8.2% excluding COVID-19 testing. Medical Devices led growth with 13.3% organic increase, driven by strong performance in Diabetes Care, Structural Heart, and Electrophysiology. The company posted GAAP EPS of $0.94 and adjusted EPS of $1.21.The company raised its full-year 2024 adjusted EPS guidance to $4.64-$4.70, reflecting continued momentum across its diversified portfolio. Abbott's board authorized a new $7 billion share repurchase program in October. Notable developments include a partnership with Medtronic for CGM integration and the U.S. launch of Lingo, Abbott's first over-the-counter continuous glucose monitoring system.Regional performance showed U.S. sales growing 10.1% to $4.2 billion, while international sales increased 1.7% to $6.4 billion. The company maintained its full-year 2024 organic sales growth guidance of 9.5-10.0%, excluding COVID-19 testing sales, which declined to $265 million in Q3 compared to $305 million last year.
雅培報告2024年第三季度銷售額爲106億，同比增長4.9%，不包括COVID-19檢測的有機銷售增長爲8.2%。醫療設備以13.3%的有機增長引領增長，得益於糖尿病護理、結構性心臟疾病和心臟電生理領域的強勁表現。公司公佈的公認會計原則每股收益爲0.94美元，調整後的每股收益爲1.21美元。公司將2024全年調整後的每股收益指導提升至4.64-4.70美元，反映出其多元化產品組合持續增長的勢頭。雅培董事會在10月授權了一項新的70億美元股票回購計劃。值得注意的發展包括與美敦力在CGM集成上的合作，以及雅培首個非處方連續血糖監測系統Lingo在美國的上市。區域業績顯示，美國銷售增長10.1%，達到42億，而國際銷售增長1.7%，達到64億。公司維持2024年全年有機銷售增長指導爲9.5-10.0%，不包括COVID-19檢測銷售，第三季度此項銷售下降至26500萬美元，去年爲30500萬美元。
雅培報告2024年第三季度銷售額爲106億，同比增長4.9%，不包括COVID-19檢測的有機銷售增長爲8.2%。醫療設備以13.3%的有機增長引領增長，得益於糖尿病護理、結構性心臟疾病和心臟電生理領域的強勁表現。公司公佈的公認會計原則每股收益爲0.94美元，調整後的每股收益爲1.21美元。公司將2024全年調整後的每股收益指導提升至4.64-4.70美元，反映出其多元化產品組合持續增長的勢頭。雅培董事會在10月授權了一項新的70億美元股票回購計劃。值得注意的發展包括與美敦力在CGM集成上的合作，以及雅培首個非處方連續血糖監測系統Lingo在美國的上市。區域業績顯示，美國銷售增長10.1%，達到42億，而國際銷售增長1.7%，達到64億。公司維持2024年全年有機銷售增長指導爲9.5-10.0%，不包括COVID-19檢測銷售，第三季度此項銷售下降至26500萬美元，去年爲30500萬美元。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    沃氪醫療
    WOK
    -- 0.570
    908 Devices
    MASS
    -- 4.480
    Vicarious Surgical
    RBOT
    -- 6.560
    Icecure Medical
    ICCM
    -- 1.176
    Apyx Medical
    APYX
    -- 1.370
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點